Dr Lal PathLabs reported a 19.6 per cent rise in Q2FY27 revenue to ₹874 crore as sample volumes grew 13.6 per cent and patient coverage increased 9 per cent
The combined Maharashtra business is expected to generate around ₹500 crore in revenue this year, with plans to establish a presence in every district headquarters
Stocks to buy today: IDBI Bank has moved above both its 50-day EMA, which indicates that the near-term trend is turning positive, says Sachin Gupta of Choice Broking.
The ₹168 crore acquisition of a 70 per cent stake in SN Genelab is expected to strengthen Dr Lal's genomics expertise and broaden its advanced diagnostics portfolio
Brokerages expect diagnostic majors to sustain volume growth through FY27, aided by robust demand and stable pricing, though the recent stock rally may cap upside
Geographically, DCB has a diversified pan-India presence with a stronger footprint across western and southern India, while continuing to expand selectively into underpenetrated markets.
Dr Lal PathLabs' share price jumped 8 per cent to a fresh 52-week high of ₹1,893.65 on the BSE today. The company has posted a better-than-expected Q1 show, prompting analysts to raise target prices.
Care Ratings expects Dr Lal PathLabs' revenue to grow by 11-12 per cent per annum in the near-to-medium term driven by organic demand growth, its expanding geographical presence and new initiatives.
Metropolis Healthcare share hit a 52-week high of ₹574.45, surging 14 per cent in trade. Thyrocare soared 12 per cent to ₹526.10, while Vijaya Diagnostic Centre gained 7 per cent to ₹1,298.45.
Diagnostics firm reports profit decline due to prior-year tax benefit, while revenue growth remains strong on higher sample volumes and improved test mix
